The diagnostic paradigm for Alzheimer's disease is shifting toward blood-based biomarkers, with clinicians sequencing plasma p-tau217 and beta-amyloid 42/40 testing as first-line tools. While payer coverage for these tests has seen few denials, broader access barriers remain for younger and commercially insured patients. Concurrently, a review by Hofstra University and Northwell Health researchers suggests ionizing radiation exposure may accelerate Alzheimer's-like neurodegeneration via eCIRP protein release and tau phosphorylation, finding an 11% increase in dementia risk per 100 mSv of cumulative exposure.
First-line diagnostic workflow for Alzheimer's
- ▪A panel of expert neurology and primary care clinicians outlined a first-line diagnostic workup for Alzheimer's disease that sequences plasma p-tau217 and beta-amyloid 42/40 testing alongside cognitive screening.
- ▪The clinical diagnostic workflow for Alzheimer's disease reserves confirmatory amyloid PET or cerebrospinal fluid testing for inconclusive cases.
Insurance coverage and patient access
- ▪A gap exists between expanded Medicare coverage for Alzheimer's disease and real-world access, particularly regarding barriers facing younger and commercially insured patients.
- ▪Payer coverage for blood-based Alzheimer's disease biomarker tests has been largely free of denials, according to clinical panelists.
Challenges in biomarker reproducibility
- ▪The transfer of candidate biomarkers to clinical practice is limited because many show promising performance in initial studies but fail to reproduce in independent cohorts or degrade under real-world heterogeneity.
- ▪Reproducibility in biomarker development is challenged by cohort-specific effects, pre-analytical variability, platform drift, batch effects, and confounding factors from concomitant diseases and treatments.
Ionizing radiation and dementia risk
- ▪Research indicates that ionizing radiation triggers DNA damage and brain immune cell responses that release the protein eCIRP, which appears to cause phosphorylation in tau proteins.
- ▪A meta-analysis of 18 studies conducted by researchers from Hofstra University and Northwell Health found an 11 percent increase in dementia risk for every 100 millisieverts of cumulative radiation exposure.
- ▪A review published in Frontiers in Immunology by researchers from Hofstra University and Northwell Health suggests that exposure to ionizing radiation may trigger biological changes in the brain resembling Alzheimer's disease.
Debatable claims
- ▪Commercial insurers should cover blood-based Alzheimer's biomarker tests to the same extent as Medicare
- ▪Blood-based biomarkers are reliable enough to serve as the primary screening tool for Alzheimer's
- ▪Cumulative radiation from routine medical imaging poses an unacceptable risk of cognitive decline
Story comments
Loading comments…